Author: Ravi Shankar

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Encore Technologies Corp. (“Encore” or the “Company”) (CSE: ENCR) is pleased to highlight a major on-orbit technology milestone achieved by portfolio company, Solstar Space Co. (“Solstar”), following the successful demonstration of Solstar’s space communications technology during an ongoing NASA proximity operations mission.

Highlights:

• NASA Mission Success: Solstar successfully demonstrated its technology in space during an operational NASA mission.
• Technology Validated in Orbit: Solstar connected two spacecraft and helped deliver NASA mission data back to Earth on the Iridium Network.
• Encore Expands Space Focus: Following its US$1.16 million investment in Solstar, Encore is strengthening its focus and leadership in the rapidly growing space sector.

The milestone comes shortly after Encore’s approximately US$1.16 million strategic investment in Solstar and represents an important validation of the investment thesis behind Encore’s growing exposure to the commercial space economy.

Encore is also announcing the appointment of Company co-founder and capital markets executive Matthew Sroka to its Board of Directors as part of a board reconstitution that will see founding shareholder and Director James Reid resign from the board of directors.

With its investment in Solstar and the recent addition of former Commander of the Royal Canadian Air Force Lieutenant-General (Ret’d) Michael Hood as Strategic Advisor, Encore is building deeper expertise and exposure within the rapidly developing commercial and defence space infrastructure markets.

Solstar Technology Successfully Deployed in Operational NASA Mission

Solstar recently demonstrated its Deke™ Space Communicator during NASA’s R5-S10 proximity operations mission involving NASA’s CubeSat and Momentus’ Vigoride-7 orbital service vehicle.

Solstar’s technology established a space-to-space Wi-Fi connection between the spacecraft, capturing mission imagery and sensor data and relaying mission-critical information back to NASA personnel at Johnson Space Center through the Iridium satellite network. During approximately 30 minutes of proximity operations, Deke collected more than 2,300 files, including imagery and optical, infrared and LiDAR sensor data.

The mission represents a significant milestone for Solstar, advancing its communications architecture from technology development to demonstrated on-orbit capability during an operational NASA mission. The demonstration validated key elements of an end-to-end communications architecture designed to support increasingly connected and autonomous space operations, with potential applications across satellites, orbital servicing, commercial space stations and future lunar operations.

For Encore, the successful mission provides important validation of its investment thesis in Solstar, demonstrating the technology in a live orbital environment alongside NASA, Momentus and Iridium, while reinforcing Encore’s growing focus on the commercial space economy.

Solstar’s Joint News Release with NASA

Stephen Kukucha, Chief Executive Officer of Encore, commented:

“When we invested in Solstar, we believed communications infrastructure would become increasingly critical as activity in orbit expands. What Solstar has now accomplished with NASA is an important validation of that thesis.

This wasn’t a laboratory demonstration. Solstar’s technology operated in space during a NASA mission, connected spacecraft in orbit and helped move mission data back to Earth through the Iridium network. That is an important distinction.

We believe the next generation of space infrastructure will require persistent and reliable connectivity between spacecraft, operators and Earth. Solstar is building technology aimed directly at that requirement, and we believe this successful mission materially strengthens its position as the commercial space economy develops.”

Board Reconstitution

Encore is also pleased to announce the appointment of Matthew Sroka, a co-founder of Encore and Managing Partner of Three Peaks Capital, to the Company’s Board of Directors.

Mr. Sroka has more than 16 years of experience across international capital markets, corporate finance and company formation. He has played a senior role in more than $200 million of public and private financings and has helped build, finance and structure companies and transactions across multiple international markets and stock exchanges. His experience spans capital formation, corporate structuring, M&A, institutional investor development and the advancement of emerging companies from early-stage formation through public-market growth.

Mr. Sroka’s appointment adds significant capital markets and corporate development experience to the Board as Encore evaluates opportunities to expand its exposure to emerging technology and infrastructure markets.

In connection with the Board reconstitution, James Reid will resign as a director of the Company.

Encore extends its sincere appreciation to Mr. Reid for his contributions as a founding director and for his important role in guiding the Company through its formation and successful listing on the Canadian Securities Exchange.

About Solstar Space Company

Solstar is a U.S.-based communications infrastructure company developing connectivity solutions for the growing space economy. The Company is focused on enabling persistent communications for spacecraft, commercial space operators, government agencies and future space-based infrastructure through a combination of communications hardware, software and communications services. Solstar’s DEKE Space Communicator is currently operating in orbit, supporting the Company’s mission of extending connectivity beyond traditional terrestrial networks.

About Encore Technologies Inc.

Encore Technologies Inc. is a technology-focused public company advancing intelligent infrastructure solutions and evaluating strategic opportunities in emerging technology sectors. The Company seeks to identify technologies and partnerships that have the potential to improve connectivity, operational efficiency and long-term infrastructure resilience.

For further information contact:
Stephen Kukucha
Chief Executive Officer
Tel: (604) 398-4786

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes statements regarding, the proposed Financing, the proposed Investment, the execution of definitive agreements, the use of proceeds, anticipated strategic benefits, potential future collaboration opportunities between Encore and Solstar, the completion of the transactions described herein, and other statements that are not historical facts. Forward-looking information is generally identified by words such as “expects,” “intends,” “anticipates,” “believes,” “plans,” “estimates,” “may,” “could,” “would,” “should,” and similar expressions. Forward-looking information reflects management’s current beliefs and assumptions and is subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise forward-looking information except as required by applicable law.

The CSE has neither approved nor disapproved the contents of this news release. The CSE does not accept responsibility for the adequacy or accuracy of this news release.

NASHVILLE, Tenn., Oct. 22, 2026 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced the date for the release of its third quarter 2026 financial results.

Third Quarter 2026 Results        
Holley will host a conference call and live webcast on Thursday, November 5, 2026, at 8:30 am (Eastern Time) to discuss the Company’s third quarter 2026 financial results. The Company’s earnings release and presentation for the third quarter 2026 will be issued before the market opens on Thursday, November 5, 2026, and will be available on the Investor Relations page of the Company’s website at investor.holley.com.

Hosting the call will be Holley Inc. President and Chief Executive Officer, Matthew Stevenson, and Chief Financial Officer, Jesse Weaver.                        

Date:	Thursday, November 5, 2026
Time:	8:30 a.m. Eastern Time
Dial-In #:	United States: 1-877-407-4019 (Toll Free)
	United States: 1-201-689-8337 (Toll)

Access Code: 13763297
        
Alternatively, the conference call will be webcast at:

Event URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=n5skJ2NR

For those unable to participate, a telephone replay recording will be available until Thursday, November 12, 2026. To access the replay, please call 877-660-6853 (Toll Free) or 201-612-7415 (Toll) and enter confirmation code 13763297. A web-based archive of the conference call will also be available at the Company’s website.

About Holley Performance Brands
Holley Performance Brands (NYSE: HLLY) is home to a portfolio of iconic brands that serve enthusiasts across the high-performance aftermarket. The company designs, engineers, manufactures and markets category-leading products and solutions for automotive enthusiasts through a focused portfolio spanning four consumer vertical groupings: American Performance, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. For more than a century, Holley has built its reputation through innovation, technical expertise and a deep understanding of enthusiast culture. For more information, visit https://www.holley.com.

Contact:        
Investor Relations: 
Sloan Bohlen / Jenna Kozlowski
Solebury Strategic Communications
203-428-3225
holley@soleburystrat.com

Media Relations Contacts: 
Nathan Espinosa / Patrick Curtin
Kahn Media
818-881-5246
holley@kahnmedia.com 

AAA Four Diamond property becomes MBody’s first multi-year commercial partner in Florida, extending the company’s physical AI business beyond casino-resorts

Highlights

• First non-casino resort customer and first commercial account in Florida.
• MBody will provide Caribe Royale Orlando physical AI hardware, service & its proprietary Orchestrator™ software.

LAS VEGAS and ORLANDO, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (Nasdaq: MBAI) today announced Caribe Royale Orlando as a new commercial partner. The AAA Four Diamond property is MBody’s first commercial resort partnership in Florida.

Proprietary MBody AI Orchestrator™ platform coordinates autonomous equipment from different manufacturers. The Company combines the software with deployment and ongoing service through its AI-as-a-Service model, which is built around multiyear subscriptions.

Caribe Royale Orlando brings the scale of a major convention destination together with the personal attention of an independently owned resort. Its AAA Four Diamond property features 1,217 one-bedroom suites, 120 two-bedroom villas and 260,000 square feet of indoor and outdoor event space. Eight dining venues, including The Venetian Chop House and Stadium Club, serve guests whose visits range from family vacations to large conferences.

Delivering a consistent experience across those settings takes a coordinated effort behind the scenes. The new relationship brings MBody AI’s offering to a resort where the quality of daily operations is part of the guest experience.

“Every part of Caribe Royale Orlando should reflect the care our team puts into a guest’s stay,” said Luciano Sperduto, Hotel Manager of Caribe Royale Orlando. “We’re thoughtful about the technology we bring into the resort. Working with MBody gives us the physical AI to support our team as we continue investing in the experience we deliver.”

“Caribe Royale Orlando combines the character of an independently owned resort with the scale of a major convention destination,” said John Fowler, Chief Executive Officer of MBody AI. “Luciano and his team understand that an exceptional guest experience depends on what happens behind the scenes. Our focus is helping them put physical AI to practical use in daily operations, supporting their people so they can devote more attention to the service that makes guests return while simultaneously lower their own operating costs.”

MBody’s proprietary AI Orchestrator platform coordinates autonomous equipment from multiple manufacturers, backed by deployment and ongoing service. Caribe Royale Orlando becomes MBody’s first resort partner that is not affiliated with a casino and first commercial deployment in Florida, extending its business beyond gaming. MBody’s strategy is to build lasting customer relationships by making Orchestrator useful across more of their operations. As customers add applications, they can address additional operating needs through a platform they already use, while MBody grows recurring software and service fees alongside the work it supports.

Follow the Company’s progress at ir.mbody.ai

About MBody AI Ltd.

MBody AI Ltd. (Nasdaq: MBAI) is building the enterprise operating layer for physical AI. Its proprietary MBody AI Orchestrator platform manages supported robots from multiple manufacturers, with a commercial focus on hospitality and gaming. MBody combines software, deployment and service under long-term agreements to help customers put robotic workforces to work. Learn more at ir.mbody.ai.

Forward-looking statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements in quotations, headlines, highlights and graphics. These statements concern expected benefits of the Caribe Royale Orlando relationship and support for resort operations; growth in standalone resorts and Florida; continuation and expansion of customer relationships; future capabilities and adoption of MBody AI Orchestrator; and growth through additional applications, hardware integrations, properties and customers. Words such as “expect,” “believe,” “intend,” “may,” “will” and similar expressions identify some, but not all, forward-looking statements.

These statements reflect management’s current expectations and assumptions regarding customer demand, technology performance, supplier availability and the Company’s financing and service capacity. Actual results may differ materially due to risks including equipment or software failures, integration difficulties, cybersecurity incidents or service interruptions; anticipated benefits not being achieved or sustained; changes in customer requirements or budgets; customer concentration, reduced orders, termination or non-renewal of engagements; delays in developing supported applications or integrations; dependence on third-party manufacturers and suppliers; equipment, personnel and service availability and costs; inability to convert pilots or expand accounts; competition and market conditions; additional capital requirements, financing availability and potential dilution; failure to maintain Nasdaq listing compliance or foreign private issuer status; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Past results and customer expansion do not guarantee future performance, further orders or deployments at other properties. Forward-looking statements are not guarantees of future operating results. Readers should not place undue reliance on these statements, which speak only as of this release’s date. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements for new information, future events or otherwise.

Quick Facts

Issuer:	MBody AI Ltd. (NASDAQ: MBAI)
Listing:	Nasdaq Capital Markets
Sector:	Technology
Industry:	Embodied AI and enterprise robotics (physical AI)
Event:	New Customer Announcement. First resort customer in Florida
Caribe Royale Orlando	AAA Four Diamond property, 1,217 one-bedroom suites, 120 two-bedroom villas and 260,000 square feet of indoor and outdoor event space
Location:	8101 World Center Drive, Orlando, Florida 32821
CUSIP	M6S83C106

Investor relations
Lytham Partners, LLC
602-889-9700 | ir@mbody.ai

Media contact
Core IR | ir@mbody.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73fed1aa-ddd2-4107-bbdd-3550457432be.

Courses generate at runtime in their true surroundings, so the library keeps growing while installs stay light across 19 launch monitors and every TruGolf Links franchise location

E6 by TruGolf generates each course at runtime in its true surroundings using Cesium for Unreal.

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) — TruGolf Holdings, Inc. (Nasdaq: TRUG) today announced that E6 by TruGolf now offers more than 15,000 real-world golf courses on demand, up 50% in under a year. Because courses are delivered on demand, the library can keep growing without making the software heavier to install. Because E6 supports 19 launch monitors, every new course reaches golfers who own other brands’ hardware. Because every TruGolf Links franchise location runs E6, the whole franchise network plays on the same platform and library.

The enabling technology is Cesium for Unreal. E6 generates each course at runtime, places it at its true location on the globe, and delivers only the data a player’s round requires. That keeps the application responsive, reduces bandwidth and storage costs, and lets golfers move from one course to the next almost immediately. Cesium, part of Bentley Systems, Incorporated (Nasdaq: BSY), has published a user story and video on TruGolf’s work at cesium.com.

E6 in numbers

• On-demand course play in E6 Golf 2026 grew nearly sixfold year over year.
• Golfers explored more than four times as many on-demand courses as the year before.
• Shots played on on-demand courses grew more than sevenfold year over year.
• Rounds played on E6 Golf 2026 more than tripled year over year.
• On-demand courses now account for more than 40% of course rounds in E6 Golf 2026, up from about 30% a year ago.
• Golfers have hit hundreds of millions of shots on the E6 platform since 2022.

“Software is where this business compounds,” said Brenner Adams, TruGolf’s Chief Executive Officer. “Every course we add makes E6 more valuable to every subscriber and venue already on it, and it adds nothing to the install. Because E6 runs on 19 launch monitors, our market is every golfer with a simulator, not only golfers with our hardware. And every TruGolf Links franchise location opens with the full library from day one. That is a recurring software business that scales with its content.”

Each course is built from a combination of public and high-resolution private datasets, processed to support accurate ball physics. Cesium ion then streams the world around it, including Google Photorealistic 3D Tiles and Bing Maps imagery, and Cesium’s geospatial coordinate systems place every dataset at its true location. TruGolf adds auto-populated vegetation and player controls for time of day, weather, and atmospheric effects. A player can tee off in Las Vegas with the Sphere on the skyline, putt along the coast at Pebble Beach, or play Park City with the Wasatch Mountains rising behind the green.

“Golfers judge a simulator by two things: how many courses they can play and how real those courses feel,” said Jake Johnson, VP Software at TruGolf. “Delivering each course on demand lets us keep adding to a library of more than 15,000 courses without asking players to download large amounts of data to their devices. Cesium surrounds every one of those courses with the real world, rendered with stunning accuracy. That combination is what lets the platform scale.”

E6 reads a player’s swing through launch monitors that use camera or LiDAR sensors to measure spin, speed, and impact, and turns that data into realistic ball flight and detailed analytics that help players improve. E6 is used in restaurants and hospitality venues, dedicated golf centers, TruGolf Links franchise locations, and home game rooms worldwide.

“TruGolf demonstrates the power of real-world data to create highly realistic, immersive simulation environments,” said Jillian Long, Business Development Manager, Cesium. “Golfers stand in the actual landscape of each course, streamed on demand from Cesium ion.”

See E6 in action

Video: youtu.be/dhlmSTiEzkQ

Cesium user story: cesium.com/blog/2026/10/22/trugolf-creates-courses-in-cesium-for-unreal

Investors: investors@trugolf.com

About TruGolf

Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf’s mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology, because TruGolf believes Golf is for Everyone. TruGolf’s team has built award-winning video games (“Links”), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6. Since TruGolf’s beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology.

About Cesium

Cesium is the open platform for creating 3D geospatial applications. Cesium has created open source offerings like CesiumJS, Cesium for Unreal, and Cesium for Unity, as well as 3D Tiles, the Open Geospatial Consortium community standard for streaming massive 3D geospatial datasets. Cesium is part of Bentley Systems, Incorporated (Nasdaq: BSY). Learn more at cesium.com.

Forward-Looking Statements

This news release contains certain statements that constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such statements that are not of historical fact constitute “forward-looking statements” and accordingly, involve estimates, assumptions, forecasts, judgments and uncertainties. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include, without limitation, statements regarding TruGolf’s expectations concerning the continued expansion of the E6 course library, future growth in user engagement, rounds played, shots played, adoption of on-demand course offerings, the scalability and performance of the E6 platform, the benefits of the Company’s technology and content strategy, the growth and operation of TruGolf Links franchise locations, and other statements that are not historical facts. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. These risks and uncertainties include, among others, changes in market conditions, customer demand and adoption of the Company’s products and services, the Company’s ability to continue expanding and enhancing the E6 platform and course library, the availability and performance of third-party technologies and data sources, the success of the Company’s franchise and software initiatives, competitive pressures, and economic conditions. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

Contacts

Investors: investors@trugolf.com
Media: press@polymath.network

###

Attachment

• TruGolf Holdings, Inc.

LOS ANGELES, Oct. 22, 2026 (GLOBE NEWSWIRE) — Playboy, Inc. (Nasdaq: PLBY) (“Playboy” or the “Company”), a global pleasure and leisure company, will release financial results for the third quarter ended September 30, 2026 after Nasdaq closes on Thursday, November 5, 2026.

Management will host an investor conference call at 5:00 p.m. Eastern time on Thursday, November 5, 2026, to discuss the Company’s third quarter 2026 financial results, provide a corporate update, and conclude with taking questions from telephone participants. To participate, please use the following information:

Q3 2026 Earnings Conference Call
Date: Thursday, November 5, 2026
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-423-9813
International Dial-in: 1-201-689-8573
Conference ID: 13762643
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1776030&tp_key=ac4d988b5b

Please join at least five minutes before the start of the call to ensure timely participation.

A telephone playback of the call will be available through Saturday, December 5, 2026. To listen, please call 1-844-512-2921, using replay pin number 13762643. A webcast replay will be available using the webcast link above.

About Playboy, Inc.

Playboy (Nasdaq: PLBY) is a global pleasure and leisure company, built on one of the most globally recognized brands. By leveraging its iconic intellectual property, Playboy pursues an asset-light model across licensing, digital content, consumer products and experiential offerings, helping consumers worldwide to live more fulfilling lives. To learn more, please visit https://investors.playboy.com.

Investor Relations Contact
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
+1 (949) 259-4987
PLBY@mzgroup.us
www.mzgroup.us

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies

EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company.

The research program is expected to commence in large animals early next year. The study will leverage StereoCED’s unique combination of targeted intracranial drug delivery and electrophysiological recording capabilities, which the Company believes is the only integrated platform of its kind. Unlike other leading drug delivery devices that are not intended for implantation, StereoCED™ is designed to support extended implantation of the electrode for less than 30 days, enabling longitudinal neurological EEG monitoring before and after drug administration. This capability could provide valuable insights into the therapeutic agent’s biological activity and efficacy over time.

This first pharmaceutical industry purchase order represents a significant commercial milestone for NeuroOne and an important step in its strategy to establish StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry. By engaging with pharmaceutical partners early in therapeutic development, NeuroOne aims to establish its technology as an integral part of the drug development process. As programs advance from preclinical research through human clinical trials and potentially commercialization, continuity with an established delivery platform may reduce development complexity and create opportunities for long-term partnerships and recurring revenue.

“We said we would complete development of StereoCED™ in fiscal Q4, and we delivered,” said David Wambeke, Chief Business Officer of NeuroOne. “With our first purchase order supporting a tier 1 global pharmaceutical company and StereoCED current availability for human investigational clinical studies, we are entering an exciting new phase. We believe StereoCED offers capabilities that competing drug delivery platforms do not, which positions NeuroOne to play an important role in the development of next-generation brain therapies.”

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo^® Cortical Electrodes, Evo^® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System.

NeuroOne has also developed the StereoCED™ platform for targeted intracranial drug delivery, which is currently available for animal research and approved investigational clinical studies. StereoCED™ has not been cleared or approved by the FDA or any other regulatory agency. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for long-term collaborations with global pharmaceutical companies, the establishment of StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry.. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

Disclaimer: NeuroOne’s StereoCED™ Drug Delivery System is not approved/cleared for commercial use by any Regulatory agency.

ST. GALLEN, Switzerland, Oct. 22, 2026 (GLOBE NEWSWIRE) — Sportradar Group AG (Nasdaq: SRAD) (“Sportradar”) will release its financial and operating results for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026. Sportradar will also host an earnings call via webcast to discuss the results at 8:30 a.m. Eastern Time on Tuesday, November 3, 2026.

Those wishing to either listen to, or participate in, the earnings webcast can do so by accessing Sportradar’s Investor Relations website at https://investors.sportradar.com. Additionally, a replay will be posted on the Investor Relations website for one year after the conclusion of the event.

About Sportradar
Sportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports media and betting/gaming industries, Sportradar provides betting and iGaming operators, media and technology companies, prediction market partners and sports federations with a best-in-class range of solutions to help grow their businesses. Trusted by the world’s leading global sports organizations including the ATP, NBA and WNBA, NHL, MLB, MLS, PGA TOUR, UEFA, FIFA, CONMEBOL, AFC, and the Bundesliga, and global clients including Flutter, DraftKings, Google, Microsoft, Kalshi and Polymarket, Sportradar covers more than a million events annually across all major sports. Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocates for an integrity-driven environment for all involved.

For more information about Sportradar, please visit www.sportradar.com

Investor Relations Contact:
Jim Bombassei
j.bombassei@sportradar.com

Press Contact:
Sandra Lee
sandra.lee@sportradar.com

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 787594.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns
ir@vcel.com
+1 (734) 418-4411

– MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology –

– In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers –

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^®, today announced the signing of an MOU in Seoul, South Korea, with Samsung Medical Center (SMC), regarding a potential clinical trial in pancreatic cancer patients. Any such trial would be subject to regulatory and ethics committee approvals.

Pancreatic cancer is one of Korea’s deadliest cancers. It is now the country’s fourth leading cause of cancer death, and unlike most cancers in Korea, its death rate has continued to rise. In 2023, 9,748 Koreans were diagnosed with the disease, and its five-year relative survival rate of 17.0% is the lowest of any cancer in the country. Fewer than one in six patients are diagnosed while the cancer is still confined to the pancreas, and more than four in ten are diagnosed only after it has already spread to distant organs.

SMC is ranked fifth in the world and number one in Korea in oncology. Its Pancreatobiliary Cancer Center combines a multidisciplinary team, a fast-track pathway for diagnosis and treatment, and a high-volume surgical program that has performed more than 4,000 pancreatectomies for pancreatic cancer between 2008 and 2025.(Courtesy of SMC)

Uzi Sofer, CEO of Alpha Tau, stated: “Signing this MOU with Samsung Medical Center, one of the world’s leading medical centers, is an important step forward in our goal to bring Alpha DaRT to cancer patients wherever they are. With Korea, our pancreatic cancer program could potentially span six countries across North America, Europe, the Middle East and Asia. I am grateful for SMC’s confidence in Alpha Tau and for the opportunity to explore the potential of Alpha DaRT to benefit its patients.”

Hee-Chul Kim, EVP of Samsung Medical Center, General Director of Samsung Comprehensive Cancer Center (SCCC), stated: “Pancreatic cancer remains one of the most challenging cancers to treat, and treatment options are limited for many patients. We hope this MOU will help us explore new possibilities for these patients. We will carefully review the clinical application of Alpha DaRT and do our best to strengthen our own research capabilities.”

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to primarily affect the tumor and to spare healthy tissue surrounding it.

About Samsung Comprehensive Cancer Center

Samsung Comprehensive Cancer Center (SCCC) is guided by respect for life, striving for excellence in patient care, research, and education to help people lead healthier, happier lives. Since opening in 2008 as Korea’s first and largest cancer center of its kind, SCCC has continued to expand its capabilities, establishing the Supportive Care Center (2014), the Proton Therapy Center (2016), the CAR T-Cell Therapy Center (2021), and the Precision Oncology Therapeutics Center (2022). In 2023, SCCC signed MOUs with Gustave Roussy and Charité to strengthen its global collaboration, and in 2024 it opened the Institute for Quality of Life in Cancer. In 2026, SCCC achieved ICHOM Level 1 accreditation and signed an MOU with EORTC. SMC was ranked fifth in the world and first in Korea in oncology in Newsweek’s World’s Best Specialized Hospitals 2027.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Other than its marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer, the Alpha DaRT treatment has not been approved for commercialization or for use outside of an approved clinical trial. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic cancer patients, including a potential collaboration with Samsung Medical Center, the planned clinical trial in Korea and the timing of the required regulatory and ethics committee approvals, the potential benefits and associated risks, safety, feasibility and efficacy, future applications and uses, and other expectations, beliefs and plans, including with respect to clinical trials, regulatory approvals and studies, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

IR@alphatau.com

Samsung Medical Center Media Contact:

Su-sung Kim, Team Leader, Communications Team, Samsung Medical Center, +82-2-3410-3042,

SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2026 earnings release and conference call.

The Company will release its third quarter 2026 results on Thursday, November 5, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, November 5, 2026. The call can be accessed at 1-800-245-3047, conference ID “ICUMED”. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company’s website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Source: ICU Medical, Inc.